| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Clinical |
Authors' Affiliations: 1 Molecular Therapeutics/Drug Discovery Program, 2 Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute; 3 Division of Hematology/Oncology, Departments of Medicine and 4 Pharmacology University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and 5 Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Centers, National Cancer Institute, Bethesda, Maryland
Requests for reprints: Ramesh K. Ramanathan, UPMC Cancer Pavilion, #562 5150 Center Avenue, Pittsburgh, PA 15232. Phone: 412-648-6507; Fax: 412-648-6579; E-mail: ramanathanrk{at}upmc.edu.
Purpose: 17-(Allylamino)-17-demethoxygeldanamycin (17AAG), a benzoquinone antibiotic, down-regulates oncoproteins by binding specifically to heat shock protein 90 (HSP90). We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics.
Experimental Design: Escalating doses of 17AAG were given i.v. over 1 or 2 hours on a weekly x 3 schedule every 4 weeks to cohorts of three to six patients. Plasma pharmacokinetics of 17AAG and 17-(amino)-17-demethoxygeldanamycin (17AG) were assessed by high-performance liquid chromatography. Expression of HSP70 and HSP90 in peripheral blood mononuclear cells was measured by Western blot.
Results: Forty-five patients were enrolled to 11 dose levels between 10 and 395 mg/m2. The maximum tolerated dose was 295 mg/m2. Dose-limiting toxicity occurred in both patients (grade 3 pancreatitis and grade 3 fatigue) treated with 395 mg/m2. Common drug-related toxicities (grade 1 and 2) were fatigue, anorexia, diarrhea, nausea, and vomiting. Reversible elevations of liver enzymes occurred in 29.5% of patients. Hematologic toxicity was minimal. No objective responses were observed. 17AAG pharmacokinetics was linear. Peak plasma concentration and area under the curve of 17AG, the active major metabolite of 17AAG, increased with 17AAG dose, but the relationships were more variable than with 17AAG. 17AAG and 17AG in plasma were >90% protein bound. There were no consistent changes in peripheral blood mononuclear cell HSP90 or HSP70 content.
Conclusions: 17AAG doses between 10 and 295 mg/m2 are well tolerated. 17AAG pharmacokinetics is linear. Peripheral blood mononuclear cell HSP90 and HSP70 are uninformative pharmacodynamic markers. The dose recommended for future studies is 295 mg/m2 weekly x 3, repeated every 4 weeks.
Key Words: clinical trial • geldanamycin • heat shock proteins • phase I study
This article has been cited by other articles:
|
|
 |
|
  S. S. Ramalingam, M. J. Egorin, R. K. Ramanathan, S. C. Remick, R. P. Sikorski, T. F. Lagattuta, G. S. Chatta, D. M. Friedland, R. G. Stoller, D. M. Potter, et al. A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies Clin. Cancer Res., June 1, 2008; 14(11): 3456 - 3461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ratain and R. H. Glassman Reply to the Letter to the Editor from Banerji et al Clin. Cancer Res., April 15, 2008; 14(8): 2514 - 2514. [Full Text] [PDF]
|
|
|
|
 |
|
 U. Banerji, A. Affolter, I. Judson, R. Marais, and P. Workman BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors Mol. Cancer Ther., April 1, 2008; 7(4): 737 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Zhang, A. Hamza, X. Cao, B. Wang, S. Yu, C.-G. Zhan, and D. Sun A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells Mol. Cancer Ther., January 1, 2008; 7(1): 162 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chandarlapaty, A. Sawai, Q. Ye, A. Scott, M. Silinski, K. Huang, P. Fadden, J. Partdrige, S. Hall, P. Steed, et al. SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers Clin. Cancer Res., January 1, 2008; 14(1): 240 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Gray Jr., M. A. Stevenson, and S. K. Calderwood Targeting Cdc37 Inhibits Multiple Signaling Pathways and Induces Growth Arrest in Prostate Cancer Cells Cancer Res., December 15, 2007; 67(24): 11942 - 11950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Modi, A. T. Stopeck, M. S. Gordon, D. Mendelson, D. B. Solit, R. Bagatell, W. Ma, J. Wheler, N. Rosen, L. Norton, et al. Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2 Overexpressing Breast Cancer: A Phase I Dose-Escalation Study J. Clin. Oncol., December 1, 2007; 25(34): 5410 - 5417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Niikura, A. Dixit, R. Scott, G. Perkins, and K. Kitagawa BUB1 mediation of caspase-independent mitotic death determines cell fate J. Cell Biol., July 10, 2007; 178(2): 283 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Oh, J. K. Woo, Y. D. Yazici, J. N. Myers, W.-Y. Kim, Q. Jin, S. S. Hong, H.-J. Park, Y.-G. Suh, K.-W. Kim, et al. Structural Basis for Depletion of Heat Shock Protein 90 Client Proteins by Deguelin J Natl Cancer Inst, June 20, 2007; 99(12): 949 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Eiseman, J. Guo, R. K. Ramanathan, C. P. Belani, D. B. Solit, H. I. Scher, S. P. Ivy, E. G. Zuhowski, and M. J. Egorin Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors Clin. Cancer Res., April 1, 2007; 13(7): 2121 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Ramanathan, M. J. Egorin, J. L. Eiseman, S. Ramalingam, D. Friedland, S. S. Agarwala, S. P. Ivy, D. M. Potter, G. Chatta, E. G. Zuhowski, et al. Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers Clin. Cancer Res., March 15, 2007; 13(6): 1769 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Solit, S. P. Ivy, C. Kopil, R. Sikorski, M. J. Morris, S. F. Slovin, W. K. Kelly, A. DeLaCruz, T. Curley, G. Heller, et al. Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer Clin. Cancer Res., March 15, 2007; 13(6): 1775 - 1782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bagatell, L. Gore, M. J. Egorin, R. Ho, G. Heller, N. Boucher, E. G. Zuhowski, J. A. Whitlock, S. P. Hunger, A. Narendran, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study Clin. Cancer Res., March 15, 2007; 13(6): 1783 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Stellas, A. Karameris, and E. Patsavoudi Monoclonal Antibody 4C5 Immunostains Human Melanomas and Inhibits Melanoma Cell Invasion and Metastasis Clin. Cancer Res., March 15, 2007; 13(6): 1831 - 1838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kamynina, K. Kauppinen, F. Duan, N. Muakkassa, and D. Manor Regulation of Proto-Oncogenic Dbl by Chaperone-Controlled, Ubiquitin-Mediated Degradation Mol. Cell. Biol., March 1, 2007; 27(5): 1809 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Mitchell, M. A. Park, G. Zhang, S. I. Han, H. Harada, R. A. Franklin, A. Yacoub, P.-L. Li, P. B. Hylemon, S. Grant, et al. 17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines Mol. Cancer Ther., February 1, 2007; 6(2): 618 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Lang, G. W. Caldwell, J. Li, G. C. Leo, W. J. Jones, and J. A. Masucci Biotransformation of Geldanamycin and 17-Allylamino-17-Demethoxygeldanamycin by Human Liver Microsomes: Reductive versus Oxidative Metabolism and Implications Drug Metab. Dispos., January 1, 2007; 35(1): 21 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. McCollum, C. J. TenEyck, B. M. Sauer, D. O. Toft, and C. Erlichman Up-regulation of Heat Shock Protein 27 Induces Resistance to 17-Allylamino-Demethoxygeldanamycin through a Glutathione-Mediated Mechanism. Cancer Res., November 15, 2006; 66(22): 10967 - 10975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. WAZA, H. ADACHI, M. KATSUNO, M. MINAMIYAMA, F. TANAKA, and G. SOBUE Alleviating Neurodegeneration by an Anticancer Agent: An Hsp90 Inhibitor (17-AAG) Ann. N.Y. Acad. Sci., November 1, 2006; 1086(1): 21 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lou, N. Fatima, Z. Xiao, S. Stauffer, G. Smythers, P. Greenwald, and I. U. Ali Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1598 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chin, L. A. Garraway, and D. E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era. Genes & Dev., August 15, 2006; 20(16): 2149 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Gyurkocza, J. Plescia, C. M. Raskett, D. S. Garlick, P. A. Lowry, B. Z. Carter, M. Andreeff, M. Meli, G. Colombo, and D. C. Altieri Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst, August 2, 2006; 98(15): 1068 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Smith-Jones, D. Solit, F. Afroze, N. Rosen, and S. M. Larson Early Tumor Response to Hsp90 Therapy Using HER2 PET: Comparison with 18F-FDG PET J. Nucl. Med., May 1, 2006; 47(5): 793 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Pienta and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671. [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, A. L. Kung, F. E. Davies, G. Morgan, M. Akiyama, R. Shringarpure, N. C. Munshi, et al. Antimyeloma activity of heat shock protein-90 inhibition Blood, February 1, 2006; 107(3): 1092 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty and K. I. Block Multifocal Angiostatic Therapy: An Update Integr Cancer Ther, December 1, 2005; 4(4): 301 - 314. [Abstract] [PDF]
|
|
|
|
|
|
N. O. Ibrahim, T. Hahn, C. Franke, D. P. Stiehl, R. Wirthner, R. H. Wenger, and D. M. Katschinski Induction of the Hypoxia-Inducible Factor System by Low Levels of Heat Shock Protein 90 Inhibitors Cancer Res., December 1, 2005; 65(23): 11094 - 11100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Banerji, M. Walton, F. Raynaud, R. Grimshaw, L. Kelland, M. Valenti, I. Judson, and P. Workman Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models Clin. Cancer Res., October 1, 2005; 11(19): 7023 - 7032. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
